雷利度胺单用或联合用药治疗多发性骨髓瘤

Lenalidomide in treatment of patients with multiple myeloma

目的为了观察雷利度胺在我国多发性骨髓瘤患者中的疗效和不良反应。方法对10例多发性骨髓瘤患者采用单用雷利度胺或联合用药治疗。结果nCR1例,PR1例,MR1例,NC3例,PD4例,总有效率70.0(包括4例PD,曾经有效后进展)。中位治疗反应时间为5.1(1～16)周。不良反应:粒细胞减少3例,血小板减少1例,轻微乏力,头晕2例,过敏性皮疹1例,低钾血症1例,合并肺部感染2例,短暂性脑缺血发作1例。结论雷利度胺单用或联合用药疗效较佳,其不良反应较少,患者耐受良好,并且可以在门诊应用。

Objective To evaluate the efficacy and side effect of lenalidomide in treatment of patients with multiple myeloma. Methods Ten patients with multiple myeloma were treated with single or combination use of lenalidomide. Results Among 10 cases there was 1 CR, 1 PR, 1 MR,3 NC and 4 PD with an overall response rate of 70.0%. Median time of response was 5. 1 （1- 16）weeks. The side effects included granulopenia （3 cases）, thrombocytopenia （1 case）, fatigue and dizzy （2 cases）, allergic skin rash （1 case）, kaliopenia （1 case）, pulmonary infection （2 cases ）, transient cerebral ischemia attack （1 case）. Conclusion The efficacy of single or combination use of lenalidomide was satisfactory and the side effect was acceptable, which indicates that the drug might be administered for out-patients.